Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers

Bibliography

• Freedman R. Schizophrenia. N Engl J Med 2003;349:1738-49
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, WFSBP task force on treatment guidelines for schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. World J Biol Psychiatry 2005;21:132-91
   Google Scholar
• Kraepelin E. Dementia Praecox and Paraphrenia, 1919 (rev). In: Robertson GM, editor. Krieger; New York, NY: 1971
   Google Scholar
• Carpenter W, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008;33:2061-79
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008;371:1085-97
   PubMed Web of Science ®Google Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30
   PubMed Web of Science ®Google Scholar
• Brundtland GH. From the world health organization mental health: new understanding, new hope. JAMA 2001;286:2391
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214-19
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Text Revision. 4th edition. American Psychiatric Association; Washington, DC: 2000
   Google Scholar
• World Health Organization: Tenth revision of the International Classification of Disease, Chapter V (F): Mental and Behavioural Disorders (including disorders of psychological development). Clinical Descriptions and Diagnostical Guidelines. World Health Organization; Geneva: 1991
   Google Scholar
• Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 2008;7:22-8
   PubMed Web of Science ®Google Scholar
• Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000;14:1-21
   PubMed Web of Science ®Google Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45
   PubMed Web of Science ®Google Scholar
• Wilk CM, Gold JM, Humber K, Brief cognitive assessment in schizophrenia: normative data for the repeatable battery for the assessment of neuropsychological status. Schizophr Res 2004;70:175-86
   PubMed Web of Science ®Google Scholar
• Rodriguez-Sanchez JM, Perez-Iglesias R, Gonzalez-Blanch C, 1-year follow-up study of cognitive function in first episode non-affective psychosis. Schizophr Res 2008;104:165-74
   PubMed Web of Science ®Google Scholar
• Barch DM, Carter CS, Cohen JD. Context processing deficit in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms. J Abnorm Psychol 2003;112:132-43
   PubMed Web of Science ®Google Scholar
• Keefe RS, Bilder D, Harvey P, Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64:633-47
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Barch DM, Gold JM, Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39
   PubMed Web of Science ®Google Scholar
• Buchanan HW, Davis M, Goff D, A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:1-15
   Google Scholar
• Buchanan RW, Keefe RS, Umbricht D, The FDA-NIMH-MATRICS guidelines fro clinical trila design og cognitive-enhancing drugs: what do we know 5 years later. Scizophr Bull 2010;37:1209-17
   PubMed Web of Science ®Google Scholar
• Targacept Presents Statistically Significant Results for TC-5619 on Measures of Cognitive Dysfunction in Schizophrenia and Negative Symptoms of Schizophrenia Results from Phase 2 study presented at the International Congress on Schizophrenia Research. April 7, 2011. Available from: www.targacept.com/wt/page/pr_1302179429 [Last accessed 1 August 2011]
   Google Scholar
• Maruff P, Thomas E, Cysique L, Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 2009;24:165-78
   PubMed Web of Science ®Google Scholar
• EnVivo Announces Positive Phase 2b Clinical Data In Schizophrenia: EVP-6124 Meets Primary Endpoint with Statistically Significant Improvement in Cognition and Multiple Secondary Endpoints for Improvement in Function and Impact on Negative Symptoms. May 17, 2011. Available from www.envivopharma.com/news-releases.php [Last accessed 8 August 2011]
   Google Scholar
• Harrison G, Eaton WW. From research world to real world: routine outcome measures are the key. Curr Opin Psychiatry 1999;12:187-9
   Web of Science ®Google Scholar
• Seeman MV. Clinical trials in psychiatry: do results apply to practice? Can J Psychiatry 2001;46:352-5
   PubMed Web of Science ®Google Scholar
• Bero LA, Grilli R, Grishaw JM, Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 1998;317:465-8
   PubMed Web of Science ®Google Scholar
• Duffy FF, Chung H, Trivedi M, Systematic use of patient-rated depression severity monitoring: is it helpful and feasible in clinical psychiatry? Psychiatr Serv 2008;59:1148-54
   PubMed Web of Science ®Google Scholar
• Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45
   PubMed Web of Science ®Google Scholar
• Jablensky A. Subtyping schizophrenia: implications for genetic research. Mol Psychiatry 2006;11:815-36
   PubMed Web of Science ®Google Scholar
• Heinrichs RW, Miles AA, Smith D, Cognitive, clinical and functional characteristics of verbally superior schizophrenia patients. Neuropsychology 2008;22:321-8
   PubMed Web of Science ®Google Scholar
• Ammari N, Heinrichs RW, Miles AA. An investigation of 3 neurocognitive subtypes in schizophrenia. Schizophr Res 2010;121:32-8
   PubMed Web of Science ®Google Scholar
• Dibben CR, Rice C, Laws K, Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychol Med 2009;39:381-92
   PubMed Web of Science ®Google Scholar
• Green MF, Schooler NR, Kern RS, Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry 2001;168:400-7
   Google Scholar
• Fucetola R, Seidman LJ, Kremen WS, Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol Psychiatry 2000;48:137-46
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005;57:1377-84
   PubMed Web of Science ®Google Scholar
• Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol Clin Exp 2010;25:353-8
   PubMed Web of Science ®Google Scholar
• Goldberg TE, Keefe RSE, Goldman RS, Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 2010;35:1053-62
   PubMed Web of Science ®Google Scholar